SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
154.40    1.60 (1.05%)
Bid:
154.40
Ask:
154.80
Spread: 0.40 (0.259%)
Market Cap: £883.65m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Trading Statement

27 Oct 2017 07:00

ELEMENTIS PLC - Trading Statement

ELEMENTIS PLC - Trading Statement

PR Newswire

London, October 26

Elementis plc

Q3 Trading Update

Sustained good revenue performance and overall trading on track

Elementis plc (“Elementis” or the “Group”), a Global Specialty Chemicals Company, today issues its planned period end trading update for the three months ended 30 September 2017.

In the third quarter the Group has performed in line with expectations and seen a continuation of the trends experienced across the first half of the year.

Specialty Products performed well and in line with expectations

Coatings saw a good sales performance across all regions versus last year, however higher raw material costs impacted profit growth.

Personal Care continued to benefit from increased penetration of our hectorite based products across categories and geographies. The integration of SummitReheis remains on track with synergies well underpinned, and we continue to implement pricing responses to recover raw material cost inflation. We are creating a Personal Care business of scale.

Energy has remained strong, reflecting higher activity levels and market share gains. Momentum in the business remains extremely positive.

Chromium on track to deliver full year improvement

Chromium has continued to perform well and in line with the trends experienced across the first half of the year. Despite unplanned production outages at our Castle Hayne and Corpus Christi facilities during the third quarter we continue to expect an improved full year outcome versus 2016.

Surfactants disposal progressing well

As previously indicated, the favourable first half conditions in Surfactants have not continued. The sale process for the business is progressing well and we continue to expect resolution in early 2018.

Commenting on the performance, CEO, Paul Waterman said,

“Elementis has delivered another good revenue performance in the third quarter and overall trading is on track. Trends remain similar to those reported in the first half of the year and we remain on course to grow operating profit across all three segments in 2017. Going forward, we continue to see significant potential for Elementis as we implement our Reignite Growth strategy”.

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

Martin Robinson, Tulchan Tel: 020 7353 4200

Date   Source Headline
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights
31st Jan 20233:04 pmRNSSale of Chromium business
19th Jan 20237:00 amRNSTrading Update
3rd Jan 20239:47 amRNSTotal Voting Rights
8th Dec 20222:10 pmRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSSale of Chromium business
23rd Nov 20223:54 pmRNSHolding(s) in Company
16th Nov 20221:43 pmRNSHolding(s) in Company
10th Nov 20229:40 amRNSHolding(s) in Company
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20229:48 amRNSTotal Voting Rights
31st Oct 20223:23 pmRNSHolding(s) in Company
26th Oct 20227:00 amRNSQ3 Trading Update
18th Oct 20223:13 pmRNSHolding(s) in Company
3rd Oct 20229:39 amRNSTotal Voting Rights
29th Sep 202212:45 pmRNSDirector/PDMR Shareholding
29th Sep 202210:12 amRNSDirector/PDMR Shareholding
22nd Sep 202211:17 amRNSDirector/PDMR Shareholding
21st Sep 20224:58 pmRNSDirector/PDMR Shareholding
21st Sep 20223:48 pmRNSDirector/PDMR Shareholding
6th Sep 202212:52 pmRNSDirector Declaration
5th Sep 20224:14 pmRNSAdditional Listing
1st Sep 202212:39 pmRNSHolding(s) in Company
1st Sep 20229:15 amRNSBlock listing Interim Review
1st Sep 20229:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.